

74 Protocols Found

[Current Status Report](#) page.

Sponsor: All, Excluding Children's Oncology Group

Department: Oncology

Status: OPEN

Find

Reported: 03/27/2025 - 3:37 PM

Current Status as of today for:

Saint Vincent Hospital Cancer Center Green Bay

Protocol	NCT Number	Disease Site	Title
A032103	NCT05987241	Bladder	MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThERapy in URothelial CaNcer
S1937	NCT#04579224	Bladder	A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PDI/PDL1 Therapy
MYELOMATCH	NCT05564390	Blood Disorders-Other	MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials
NRG-BN011	NCT05095376	Brain	A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
A012301	NCT06671912	Breast	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
EAQ221CD	NCT06112613	Breast-Advanced (Metastatic/Recurrent)	Improving Medication Adherence in Metastatic BreastCancer using a CONnected CUsomized TreatmentPlatform (CONCURxP)
S1703	NCT03723928	Breast-Advanced (Metastatic/Recurrent)	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
A011801	NCT04457596	Breast-Early Stage	The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A012103	NCT05812807	Breast-Early Stage	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A191901	NCT04379570	Breast-Early Stage	Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
AFT-65	NCT05633654	Breast-Early Stage	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
CCTG-MA.39	NCT03488693	Breast-Early Stage	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
EA1211	NCT05710328	Breast-Early Stage	Interim FDG-PET/CT for PreDICTing REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial
NRG-BR007	NCT04852887	Breast-Early Stage	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
NRG-BR008	05705401	Breast-Early Stage	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
NRG-BR009	NCT05879926	Breast-Early Stage	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
S2206	NCT06058377	Breast-Early Stage	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
S2212	NCT05929768	Breast-Early Stage	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

DCP-001		Cancer Control-Other	Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
EAQ202	NCT05108298	Cancer Control-Other	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
URCC-19075	NCT04888988	Cancer Control-Other	Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NRG-CC005	NCT05080673	Colon	FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
NRG-GI008	NCT05174169	Colon	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
A022104	NCT05610163	Colon and Rectal	The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer
WF-1806	NCT03998202	Colon and Rectal	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
S2303	NCT06203600	Esophageal	Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
A022102	NCT05677490	GI Cancers-Miscellaneous	A randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma
EA2183	NCT04248452	GI Cancers-Miscellaneous	A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
GI-1810	NCT04660760	GI Cancers-Miscellaneous	Ramucirumab Plus trifluridine/tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-inferiority Phase 2 Study
EAY191-N4	NCT05554328	GYN-Miscellaneous	A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial"
EAY191-N5	NCT06126276	GYN-Miscellaneous	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EA3191	NCT04671667	Head and Neck	A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
RTOG-1216	NCT01810913	Head and Neck	Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
MM10A-EA02	NCT06317649	Leukemia-Acute Myelogenic Leukemia (AML)	A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
MM1YA-CTG01	NCT05554393	Leukemia-Acute Myelogenic Leukemia (AML)	A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
MM1YA-S01	NCT05554406	Leukemia-Acute Myelogenic Leukemia (AML)	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
S1925	NCT04269902	Leukemia-Chronic Lymphocytic Leukemia (CLL)	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
A081801	NCT04267848	Lung- Non-Small Cell Lung Cancer	Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
LungMAP	NCT03851445	Lung- Non-Small Cell Lung Cancer	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
NRG-LU008	NCT05624996	Lung- Non-Small Cell Lung Cancer	Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

NRG-LU007	NCT04402788	Lung- Small Cell Lung Cancer	Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
AHOD2131	NCT05675410	Lymphoma-Hodgkin's	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
EAQ211	NCT06002828	Lymphoma-Hodgkin's	Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
S1918	NCT04799275	Lymphoma-Non Hodgkin's	A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements
A091903	NCT05111574	Melanoma	A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
2021-05		Multiple Disease Sites	Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
A211901	NCT05008848	Multiple Disease Sites	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102	NCT05334069	Multiple Disease Sites	Blinded Reference Set For Multicancer Early Detection Blood Tests
A222004	NCT04939090	Multiple Disease Sites	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
AGCT1531	NCT03067181	Multiple Disease Sites	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
EAY191	NCT05564377	Multiple Disease Sites	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	NCT05554367	Multiple Disease Sites	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
S2013	NCT04871542	Multiple Disease Sites	Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
URCC-18007	NCT03996265	Multiple Disease Sites	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
URCC-19178	NCT05006482	Multiple Disease Sites	Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy
URCC-19185	NCT04829539	Multiple Disease Sites	Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
URCC-21038	NCT05364086	Multiple Disease Sites	Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
URCC-22063	NCT06073431	Multiple Disease Sites	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
WF2304/A172401	NCT06418204	Multiple Disease Sites	Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
A062101	NCT06232044	Multiple Myeloma	A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Ixerdotide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
EAA173	NCT03937635	Multiple Myeloma	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
EAA181	NCT04566328	Multiple Myeloma	Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
S2209	NCT05561387	Multiple Myeloma	A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
ALTE2131	NCT06513962	Ovarian	Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
NRG-CC008	NCT04251052	Ovarian	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]

NRG-GY036	NCT06580314	Ovarian	A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
EA2192	NCT04858334	Pancreas	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
EA8184	NCT04597359	Prostate	A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
NRG-GU009	NCT04513717	Prostate	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
NRG-GU010	NCT05050084	Prostate	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU013	NCT05946213	Prostate	The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
URCC-22053	NCT05838716	Prostate	High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
AGCT1532	NCT02582697	Solid Tumor- Other	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
NRG-GY026	NCT05256225	Uterine-Endometrial	A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma